Gene · 2925
Papers2,036
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,036
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Biodistribution of the Bombesin Receptor-Targeted Radiopharmaceutical Precursor BBN/C1-C2 in a Prostate Cancer Model. | Sovrem Tekhnologii Med | 2025 | 41684873 | PubTator, text mining | PubMed |
| Functional D- and L‑Naphthalenediimide-Peptides: Microwave-Driven Synthesis, Supramolecular Aggregation, and Multiphoton Fluorescence Lifetime Imaging Microscopy in Living Cells. | ACS Bio Med Chem Au | 2025 | 41425801 | PubTator, text mining | PubMed |
| The Role of Nuclear Medicine in Prostate Cancer. | Diagnostics (Basel) | 2025 | 41300900 | PubTator, text mining | PubMed |
| The gastrin-releasing peptide receptor as a potential biomarker for squamous cell carcinoma. | Sci Rep | 2025 | 41266536 | PubTator, text mining | PubMed |
| Molecular targets and the emerging role of copper radionuclides in prostate cancer theranostics. | EJNMMI Res | 2025 | 41251982 | PubTator, text mining | PubMed |
| Improving GRPR-targeting peptides for radiotheranostics application: insights from chelator modifications and α-methyl-L tryptophan substitution. | EJNMMI Radiopharm Chem | 2025 | 41231375 | PubTator, text mining | PubMed |
| Radioligand Therapy in Cancer Management: A Global Perspective. | Cancers (Basel) | 2025 | 41228206 | PubTator, text mining | PubMed |
| Butylated Neuropeptide Antagonist Targeting Hypoxia-Induced GRPR Overexpression in Small Cell Lung Cancer. | Int J Mol Sci | 2025 | 41226822 | PubTator, text mining | PubMed |
| Prostate Cancer Imaging Beyond PSMA: Applications of GRPR, AR, and Amino Acid Tracers. | Diagnostics (Basel) | 2025 | 41226028 | PubTator, text mining | PubMed |
| Regional encoding of enteric nervous system responses to microbiota and type 2 inflammation. | Science | 2025 | 41166460 | PubTator, text mining | PubMed |
| Phase I Clinical Study with the GRPR-Antagonist [99mTc]Tc-DB8 for SPECT Imaging of Prostate Cancer: Does the Injected Peptide Mass Make a Difference? | Pharmaceutics | 2025 | 41155959 | PubTator, text mining | PubMed |
| In vivo gastrin releasing peptide receptor expression in SDH deficient wild-type gastrointestinal stromal tumours (GIST): potential for theranostic applications. | EJNMMI Res | 2025 | 41118055 | PubTator, text mining | PubMed |
| Linker modifications in radiolabeled RM26-based antagonists to gastrin-releasing peptide receptor (GRPR) improved tracers' pharmacokinetics. | Eur J Pharm Sci | 2025 | 41093148 | PubTator, text mining | PubMed |
| Gastrin-Releasing Peptide Receptors Stimulate MAPK-Mediated Growth of Lung Cancer Cells by Transactivating HER4 in a Neuregulin-1, MAP Kinase-Dependent Manner Requiring Activation of the ROS-System. | Biology (Basel) | 2025 | 41007372 | PubTator, text mining | PubMed |
| PET/CT in breast cancer. | Rev Esp Med Nucl Imagen Mol (Engl Ed) | 2025 | 40914389 | PubTator, text mining | PubMed |
| Studies on the impact of modifications at the Gln-Trp site in RM2-based GRPR ligands. | EJNMMI Res | 2025 | 40890559 | PubTator, text mining | PubMed |
| The Impact of the Injected Mass of the Gastrin-Releasing Peptide Receptor Antagonist on Uptake in Breast Cancer: Lessons from a Phase I Trial of [99mTc]Tc-DB8. | Pharmaceutics | 2025 | 40871022 | PubTator, text mining | PubMed |
| Emerging PET Imaging Agents and Targeted Radioligand Therapy: A Review of Clinical Applications and Trials. | Tomography | 2025 | 40863874 | PubTator, text mining | PubMed |
| Mechanistic Insights and Clinical Implications of ELK1 in Solid Tumors: A Narrative Review. | Cells | 2025 | 40862737 | PubTator, text mining | PubMed |
| Evolution of the Jawed Vertebrate (Gnathostomata) Stomach Through Gene Repertoire Loss: Findings from Agastric Species. | J Dev Biol | 2025 | 40843895 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2925/papers?page=3